embed embed2
  • Johnson And Johnson Is Working On COVID-19 Vaccine, Commits To Supply One Billion

    Under an accelerated timeline, the company aims to initiate the first phase in September 2020.
    by SmartParenting Staff .
Johnson And Johnson Is Working On COVID-19 Vaccine, Commits To Supply One Billion
ILLUSTRATOR Natz Bade
  • Johnson & Johnson announced today it has identified a lead COVID-19 vaccine candidate (with two back-ups), which will soon head into the first manufacturing steps.

    Under an accelerated timeline, Johnson & Johnson aims to initiate the clinical study’s first phase in September 2020, with clinical data on safety and immunogenicity expected to be available by the end of the year.

    If its research and testing go according to schedule, the vaccine could be ready for emergency use in early 2021, according to Johnson & Johnson — quite the accelerated pace.

    As Johnson & Johnson pointed out in its press release, a typical vaccine development process involves several different research stages, spanning five to seven years before a vaccine candidate is even considered for approval.

    More from Smart Parenting

    Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), under the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, began efforts in January 2020, as soon as the novel coronavirus (COVID-19) sequence became available, to research potential vaccine candidates.

    ADVERTISEMENT - CONTINUE READING BELOW

    There is currently no approved vaccine, treatment, or cure for COVID-19. But aside from Johnson & Johnson, biotechnology company Moderna and researchers from the National Institutes of Health (NIH) are working on vaccine against COVID-19 called mRNA-1273. It has begun phase one of its clinical trials, and it is now testing the vaccine on humans with three different doses, Forbes reported on March 17, 2020. Read more here.

    CONTINUE READING BELOW
    Recommended Videos

    Here is the rest of the press release about Johnson & Johnson’s announcement.

    BARDA and Johnson & Johnson have committed more than $1 billion of investment to co-fund vaccine research, development, and clinical testing. The global healthcare company will use its validated vaccine platform and is allocating resources, including personnel and infrastructure globally, as needed, to focus on these efforts.

    Through collaborations with scientists at multiple academic institutions, the vaccine constructs were then tested to identify those with the most promise in producing an immune response in preclinical testing.

    ADVERTISEMENT - CONTINUE READING BELOW
    More from Smart Parenting

    Johnson & Johnson chairman and chief executive officer Alex Gorsky said, “The world is facing an urgent public health crisis, and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible.”

    He added, “As the world’s largest healthcare company, we feel a deep responsibility to improve the health of people around the world every day. Johnson & Johnson is well-positioned through our combination of scientific expertise, operational scale, and financial strength to bring our resources in collaboration with others to accelerate the fight against this pandemic.”

    As part of its commitment, Johnson & Johnson is also expanding the company’s global manufacturing capacity, including the establishment of a new U.S. manufacturing site and scaling up capacity in other countries. The additional position will assist in the rapid production of a vaccine and will enable the supply of more than one billion doses of a safe and effective vaccine globally.

    ADVERTISEMENT - CONTINUE READING BELOW
    More from Smart Parenting

Get the latest stories on COVID-19.
All you need to know from your trusted Summit Media network. Sign up here for regular updates delivered to your mailbox.
The email address you entered is invalid.
Thank you for signing up. We'll send updates directly to your inbox!
View More Stories About
Trending in Summit Network
View more articles